CoronaryAtlas logo
CoronaryAtlas
Oxidized LDL
Pathway / Lipid retention & oxidation

Oxidized LDL

lipoprotein

Oxidized LDL drives plaque formation, inflammation, and endothelial dysfunction in atherothrombotic disease.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleAnchor molecule; oxidative modification of retained lipoprotein initiates atherogenesis.
Also acts inVascular inflammation, Endothelial activation/erosion
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
61
A — assay feasibility
82
E — evidence strength
86
T1DI (composite)
37
Specificity differential (R−C)+5.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma (EDTA to limit ex-vivo oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Sandwich ELISA
Reagent / substrate
mAb 4E6 (or anti-oxLDL) capture + anti-apoB detection
Platform
ELISA plate
Turnaround · availability
Research/send-out · Research/CE

Literature evidence(60)

Showing 40 of 60 linked references.

Clinical trials(2)